The overexpression of ARHGEF2 is sufficient to increase ERK1/2 phosphorylation raising the possibility that the oncogenic potential of ARHGEF2 is partially mediated through its capacity to activate the MAPK pathway in pancreatic cancer. Here, ARHGEF2 is linked to pancreatic neoplasm.